Impact of Contextual-Level Social Determinants of Health on Newer Antidiabetic Drug Adoption in Patients with Type 2 Diabetes.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Original Publication: Basel : MDPI, c2004-

Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemic Agents*/therapeutic use ; Social Determinants of Health* ; Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use; Female ; Humans ; Male ; Middle Aged ; White People ; Adult ; Aged ; Black People

Background: We aimed to investigate the association between contextual-level social determinants of health (SDoH) and the use of novel antidiabetic drugs (ADD), including sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1a) for patients with type 2 diabetes (T2D), and whether the association varies across racial and ethnic groups.
Methods: Using electronic health records from the OneFlorida+ network, we assembled a cohort of T2D patients who initiated a second-line ADD in 2015-2020. A set of 81 contextual-level SDoH documenting social and built environment were spatiotemporally linked to individuals based on their residential histories. We assessed the association between the contextual-level SDoH and initiation of SGTL2i/GLP1a and determined their effects across racial groups, adjusting for clinical factors.
Results: Of 28,874 individuals, 61% were women, and the mean age was 58 (±15) years. Two contextual-level SDoH factors identified as significantly associated with SGLT2i/GLP1a use were neighborhood deprivation index (odds ratio [OR] 0.87, 95% confidence interval [CI] 0.81-0.94) and the percent of vacant addresses in the neighborhood (OR 0.91, 95% CI 0.85-0.98). Patients living in such neighborhoods are less likely to be prescribed with newer ADD. There was no interaction between race-ethnicity and SDoH on the use of newer ADD. However, in the overall cohort, the non-Hispanic Black individuals were less likely to use newer ADD than the non-Hispanic White individuals (OR 0.82, 95% CI 0.76-0.88).
Conclusion: Using a data-driven approach, we identified the key contextual-level SDoH factors associated with not following evidence-based treatment of T2D. Further investigations are needed to examine the mechanisms underlying these associations.

BMC Public Health. 2011 May 19;11:349. (PMID: 22182286)
JAMA Netw Open. 2021 Oct 1;4(10):e2130789. (PMID: 34714343)
Int J Health Geogr. 2016 Nov 3;15(1):38. (PMID: 27809861)
PLoS One. 2013 Aug 30;8(8):e72730. (PMID: 24023636)
Endocrine. 2014 Sep;47(1):29-48. (PMID: 24532079)
Epidemiology (Sunnyvale). 2016 Apr;6(2):. (PMID: 27274911)
Fam Community Health. 2015 Apr-Jun;38(2):169-79. (PMID: 25739064)
Int J Environ Res Public Health. 2020 Sep 14;17(18):. (PMID: 32937852)
J Urban Health. 2013 Jun;90(3):412-26. (PMID: 23188553)
N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. (PMID: 32771263)
J Transcult Nurs. 2019 May;30(3):280-290. (PMID: 30442075)
Circulation. 2020 Mar 3;141(9):e139-e596. (PMID: 31992061)
Policy Polit Nurs Pract. 2005 Feb;6(1):30-8. (PMID: 16443957)
JAMA Intern Med. 2015 Aug;175(8):1311-20. (PMID: 26121402)
Lancet Reg Health Am. 2022 Feb;6:. (PMID: 35291207)
Diabetes Res Clin Pract. 2022 May;187:109855. (PMID: 35346753)
Environ Int. 2020 Aug;141:105797. (PMID: 32413622)
Health Serv Res. 2020 Oct;55 Suppl 2:873-882. (PMID: 32880945)
JAMA Cardiol. 2016 Apr 1;1(1):9-10. (PMID: 27437646)
JAMA Netw Open. 2021 Apr 1;4(4):e216139. (PMID: 33856475)
J Prim Care Community Health. 2010 Jul 1;1(2):78-82. (PMID: 23804366)
Health Aff (Millwood). 2019 Oct;38(10):1687-1694. (PMID: 31589538)
J Am Med Inform Assoc. 2014 Mar-Apr;21(2):221-30. (PMID: 24201027)
Am J Epidemiol. 2018 Apr 1;187(4):736-745. (PMID: 29020137)
J Am Med Inform Assoc. 2016 Mar;23(2):407-12. (PMID: 26174867)
JAMA Health Forum. 2021 Dec 17;2(12):e214182. (PMID: 35977298)
Pharmacoepidemiol Drug Saf. 2019 May;28(5):632-639. (PMID: 30680840)
Ann N Y Acad Sci. 2010 Feb;1186:125-45. (PMID: 20201871)
Diabetes Care. 2018 Feb;41(2):356-363. (PMID: 29203583)
Health Psychol. 2014 Dec;33(12):1602-5. (PMID: 24295022)
BMJ. 2021 Jan 13;372:m4573. (PMID: 33441402)
Diabetes Technol Ther. 2019 Dec;21(12):702-712. (PMID: 31418588)
Environ Health Perspect. 2016 Dec;124(12):1848-1856. (PMID: 27219331)
Diabetes Care. 2022 Feb 1;45(2):372-380. (PMID: 35015080)
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. (PMID: 33298420)
J Gen Intern Med. 2020 Apr;35(4):1189-1198. (PMID: 32043258)
Health Place. 2017 Jan;43:128-137. (PMID: 28033588)
JAMA. 2002 Jul 24-31;288(4):475-82. (PMID: 12132978)
Diabetes Spectr. 2022 Spring;35(2):137-149. (PMID: 35668879)
J Urban Health. 2006 Nov;83(6):1041-62. (PMID: 17031568)

R01 DK133465 United States DK NIDDK NIH HHS

Keywords: antidiabetic drugs; neighborhood deprivation index; social determinants of health; type 2 diabetes; vacant land

0 (Hypoglycemic Agents)
0 (Sodium-Glucose Transporter 2 Inhibitors)

Date Created: 20230311 Date Completed: 20230314 Latest Revision: 20230513

20240628

PMC10001625

10.3390/ijerph20054036

36901047